Current review of cytomegalovirus in renal transplantation

L. Lopez-Rocafort, D. C. Brennan

Research output: Contribution to journalReview articlepeer-review

Abstract

Cytomegalovirus (CMV) continues to be a common cause of morbidity and mortality in transplant recipients. It has shifted from being overtly to insidiously lethal. Even with effective prophylactic and preemptive treatment strategies it is the most concerning viral agent in transplant recipients. CMV disease has been associated with the two most common causes of late graft loss; cardiovascular disease and chronic rejection. The incidence and morbidity of CMV infection and disease is probably a reflection of immunosuppressive strategies, and ability to diagnose and monitor for CMV. New molecular tests have been developed which include the antigenernia assay, the hybrid capture assay, RNA detection by nucleic acid sequence based amplification (NASBA), and DNA PCR. New insights have also been reported in the diagnostic, monitoring and treatment of the emergent problem of resistance. Nevertheless, the Holy Grail of CMV is in the development of an effective vaccination against this serious viral pathogen.

Original languageEnglish (US)
Pages (from-to)145-158
Number of pages14
JournalMinerva Urologica e Nefrologica
Volume53
Issue number3
StatePublished - Sep 1 2001
Externally publishedYes

Keywords

  • Diagnosis - Cytomegalovirus infections
  • Kidney transplantation - Cytomegalovirus infections
  • Therapy

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Current review of cytomegalovirus in renal transplantation'. Together they form a unique fingerprint.

Cite this